Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab

Publisher： Karger

E-ISSN： 1662-6575|9|1|249-254

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.1, 2016-04, pp. : 249-254

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma

By  

Oncology, Vol. 90, Iss. 6, 2016-04 ,pp. : 307-312

Karger

Access to resources Recommend Favorite

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 233-239

Karger

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐ras status for unresectable colorectal liver metastasis (BECK study)

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 8, 2015-08 ,pp. : 634-645

John Wiley & Sons Inc

Access to resources Recommend Favorite